Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2004 2
2005 1
2006 2
2010 1
2011 1
2013 1
2014 4
2015 3
2016 3
2017 5
2018 2
2019 6
2020 10
2021 5
2022 7
2023 3
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Evaluating the clinical utility of the Atopic Dermatitis Control Tool: measurement properties and agreement between patients' responses and clinicians' impressions of atopic dermatitis control.
Simpson EL, Eckert L, Gadkari A, Brown TM, Lio PA, Lockshin B, Nelson L, Fehnel SE, Mahajan P, Chao J, Nygårdas M, Guillemin I. Simpson EL, et al. Among authors: lockshin b. Br J Dermatol. 2024 May 17;190(6):917-919. doi: 10.1093/bjd/ljae056. Br J Dermatol. 2024. PMID: 38593196 No abstract available.
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial.
Cork MJ, Lockshin B, Pinter A, Chen Z, Shumel B, Prescilla R. Cork MJ, et al. Among authors: lockshin b. Acta Derm Venereol. 2024 Feb 12;104:adv13467. doi: 10.2340/actadv.v104.13467. Acta Derm Venereol. 2024. PMID: 38348724 Free PMC article. Clinical Trial.
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.
Burshtein J, Shah M, Zakria D, Lockshin B, Crowley J, Merola JF, Gordon K, Shahriari M, Korman NJ, Chovatiya R, Kalb R, Lebwohl M. Burshtein J, et al. Among authors: lockshin b. Dermatol Ther (Heidelb). 2024 Feb;14(2):323-339. doi: 10.1007/s13555-024-01099-y. Epub 2024 Feb 10. Dermatol Ther (Heidelb). 2024. PMID: 38340237 Free PMC article. Review.
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J, Ferrucci S, Lima RG, Witte MM, Xu W, ElMaraghy H, Natalie CR, Pierce E, Blauvelt A; ADhere Investigators. Simpson EL, et al. JAMA Dermatol. 2023 Feb 1;159(2):182-191. doi: 10.1001/jamadermatol.2022.5534. JAMA Dermatol. 2023. PMID: 36630140 Free PMC article. Clinical Trial.
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
Paller AS, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Gonzalez ME, Lockshin B, Chen Z, Bansal A, Levit NA, Prescilla R. Paller AS, et al. Among authors: lockshin b. Paediatr Drugs. 2023 Jan;25(1):67-77. doi: 10.1007/s40272-022-00553-8. Epub 2022 Dec 19. Paediatr Drugs. 2023. PMID: 36529811 Free PMC article. Clinical Trial.
Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial.
Gelfand JM, Shin DB, Armstrong AW, Tyring SK, Blauvelt A, Gottlieb S, Lockshin BN, Kalb RE, Fitzsimmons R, Rodante J, Parel P, Manyak GA, Mendelsohn L, Noe MH, Papadopoulos M, Syed MN, Werner TJ, Wan J, Playford MP, Alavi A, Mehta NN. Gelfand JM, et al. Among authors: lockshin bn. JAMA Dermatol. 2022 Dec 1;158(12):1394-1403. doi: 10.1001/jamadermatol.2022.3862. JAMA Dermatol. 2022. PMID: 36129688 Free PMC article. Clinical Trial.
54 results